CDH1 and cancer: The inhibition of epithelial marker E‐cadherin contributes to the emergence of TRAIL resistance, while E‐cadherin re‐expression can reverse EMT and promote the sensitivity of cancer cells to TRAIL via facilitating TRAIL apoptotic pathway.215